CRISIL Research revises Panacea Biotec’s fundamental grade to ‘2/5’

26 Apr 2012 Evaluate

Rating agency CRISIL Research has revised Panacea Biotec’s CRISIL IER fundamental grade to ‘2/5’ from ‘3/5’. The grade indicates that the company’s fundamentals are ‘moderate’ relative to other listed equity securities in India. Further, the rating agency has assigned a valuation grade of ‘3/5’ to the company.

The fundamental grade has been revised downwards after factoring in Panacea’s weak business footing following the recent delisting of oral polio vaccine (OPV) by World Health Organisation (WHO).

Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

344.65 -0.10 (-0.03%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×